2.07
3.50%
0.07
시간 외 거래:
2.10
0.03
+1.45%
전일 마감가:
$2.00
열려 있는:
$1.98
하루 거래량:
459.93K
Relative Volume:
0.41
시가총액:
$100.05M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.7964
EPS:
-2.5993
순현금흐름:
$-104.11M
1주 성능:
+2.99%
1개월 성능:
-5.91%
6개월 성능:
-36.31%
1년 성능:
+11.89%
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-03-21 | 개시 | H.C. Wainwright | Buy |
2021-10-15 | 재개 | BTIG Research | Buy |
2021-06-28 | 개시 | ROTH Capital | Buy |
2021-05-05 | 재개 | Credit Suisse | Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-01-11 | 개시 | BTIG Research | Buy |
2021-01-11 | 개시 | Credit Suisse | Outperform |
2021-01-11 | 개시 | JP Morgan | Overweight |
2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake - Yahoo Finance UK
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update - MarketBeat
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025 - Insider Monkey
You might want to take a look at BioAtla Inc (BCAB) now - SETE News
BioAtla Inc (BCAB) stock: A year of ups and downs - US Post News
Market Insights: BioAtla Inc (BCAB)’s Notable Gain of 7.25, Closing at 2.07 - The Dwinnex
636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC - Defense World
AQR Capital Management LLC Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
There is no doubt that BioAtla Inc (BCAB) ticks all the boxes. - SETE News
Bank of Montreal Can Buys 143,521 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy - Seeking Alpha
Renaissance Technologies LLC Sells 370,800 Shares of BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
Analyzing the Impact of Earnings Reports on BioAtla Inc Inc. (BCAB) Price Performance - The InvestChronicle
BioAtla to Score Up to $133M - San Diego Business Journal
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - ForexTV.com
Pleasing Signs As A Number Of Insiders Buy BioAtla Stock - Simply Wall St
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
JMP Securities gives a Mkt outperform recommendation for BioAtla Inc (BCAB) - Knox Daily
Rhumbline Advisers Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Potential Price Increase for Equinix Inc (EQIX) After Recent Insider Activity - Knox Daily
BCAB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Analyzing BCAB’s price-to-book ratio for the last quarter - US Post News
Michael Burry buys 634,000 shares of this $1 penny stockFinbold - Finbold - Finance in Bold
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress - The Manila Times
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Michael Burry just bought 633,959 shares in this $1 penny stock - Motley Fool UK
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases New Holdings in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla - The Pharma Letter
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오아틀라 주식 (BCAB) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
SHORT JAY M PHD | Chief Executive Officer |
Dec 20 '23 |
Buy |
2.14 |
50,000 |
106,910 |
1,439,283 |
STEINMAN LAWRENCE | Director |
Dec 19 '23 |
Buy |
2.05 |
20,000 |
41,048 |
38,459 |
Vasquez Christian | See Remarks |
Dec 19 '23 |
Buy |
2.04 |
7,495 |
15,262 |
115,659 |
자본화:
|
볼륨(24시간):